top of page

Australia Healthcare News | Media | Updates

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease

For women facing advanced or recurring endometrial cancer, a medication called Jemperli (dostarlimab) will be included in the Pharmaceutical Benefits Scheme (PBS).

This medication, when used alongside chemotherapy, offers a new treatment option for the cancer.

Jemperli works by helping the body's immune system target cancer cells. It is expected that around 200 women each year will benefit from this addition.

Without government assistance, the cost of treatment could exceed $139,000.

Additionally, individuals with chronic kidney disease (CKD) who experience itching during haemodialysis will now have access to a new medication called Korsuva® (Difelikefalin) under the PBS.

In 2021, approximately 15,200 Australians with kidney failure underwent dialysis, with the majority opting for haemodialysis.

Itching associated with CKD can significantly impact quality of life, affecting sleep and mood, and increasing the risk of complications such as infections and mortality.

It is estimated that around 2,800 patients each year will benefit from this new listing. Without government subsidy, the annual cost of treatment could be around $7,200.


Recent Posts

See All


bottom of page